» Articles » PMID: 12921315

Phenotype Score to Grade the Severity of Thalassemia Intermedia

Overview
Specialty Pediatrics
Date 2003 Aug 19
PMID 12921315
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Thalassemia intermedia is an ill-defined group of thalassemia patients with severity in between thalassemia major and asymptomatic carriers. The severity of cases varies greatly. With availability of information about genetic modifiers of beta-thalassemia phenotype, attempts are being made to study genotype phenotype correlation in thalassemia intermedia.

Methods: The first important step in genotype, phenotype correlation is well-defined phenotypes. Severity of thalassemia intermedia can not be graded only on haemoglobin level and age of presentation. The authors have developed a phenotype scoring system to subclassify thalassemia intermedia patients into 3 groups, viz, mild, moderate and severe.

Result: This phenotype scoring system appears to grade the severity correctly depending on various clinical features like age of presentation, severity of anaemia, growth retardation, bone marrow hyperplasia, need of blood transfusions and splenectomy.

Conclusion: The classification of thalassemia intermedia will be useful for genotype phenotype correlation, to develop management guidelines for the subgroups and to try new treatment modalities like hydroxyurea, erythropoetin etc.

Citing Articles

Non-Transfusion-Dependent Thalassemia: A Panoramic Review.

Shash H Medicina (Kaunas). 2022; 58(10).

PMID: 36295656 PMC: 9608723. DOI: 10.3390/medicina58101496.


Thalassemia Intermedia: Chelator or Not?.

Lee Y, Yen C, Lee Y, Chen R Int J Mol Sci. 2022; 23(17).

PMID: 36077584 PMC: 9456380. DOI: 10.3390/ijms231710189.


Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

Alshamsi S, Hamidi S, Narci H BMC Health Serv Res. 2022; 22(1):304.

PMID: 35248046 PMC: 8897869. DOI: 10.1186/s12913-022-07663-6.


Productivity Loss and Associated Costs Among Patients with Transfusion-Dependent Thalassemia in Dubai, United Arab Emirates.

Alshamsi S, Hamidi S, Narci H Clinicoecon Outcomes Res. 2021; 13:853-862.

PMID: 34616164 PMC: 8487795. DOI: 10.2147/CEOR.S334724.


When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.

Taher A, Radwan A, Viprakasit V Vox Sang. 2014; 108(1):1-10.

PMID: 25286743 PMC: 4302976. DOI: 10.1111/vox.12201.


References
1.
Ho P, Hall G, Luo L, Weatherall D, Thein S . Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?. Br J Haematol. 1998; 100(1):70-8. DOI: 10.1046/j.1365-2141.1998.00519.x. View

2.
Rund D, Oron-Karni V, Filon D, Goldfarb A, RACHMILEWITZ E, OPPENHEIM A . Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol. 1997; 54(1):16-22. DOI: 10.1002/(sici)1096-8652(199701)54:1<16::aid-ajh3>3.0.co;2-7. View

3.
de Castro C, Devlin B, Fleenor D, Lee M, KAUFMAN R . A novel beta-globin mutation, beta Durham-NC [beta 114 Leu-->Pro], produces a dominant thalassemia-like phenotype. Blood. 1994; 83(4):1109-16. View

4.
Camaschella C, Mazza U, Roetto A, Gottardi E, Parziale A, Travi M . Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol. 1995; 48(2):82-7. DOI: 10.1002/ajh.2830480203. View

5.
Traeger-Synodinos J, Kanavakis E, Vrettou C, Maragoudaki E, Michael T, Kattamis C . The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies. Br J Haematol. 1996; 95(3):467-71. DOI: 10.1046/j.1365-2141.1996.d01-1939.x. View